Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-18T08:16:43.998Z Has data issue: false hasContentIssue false
  • English
  • Français

Perspective of strategic plasma therapy for prognostic improvement of patients with ovarian cancer

Published online by Cambridge University Press:  28 November 2013

Hiroaki Kajiyama ,
Fumi Utsumi ,
Kae Nakamura ,
Hiromasa Tanaka ,
Masaru Hori  and
Fumitaka Kikkawa
Hiroaki Kajiyama
Affiliation:
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.
Fumi Utsumi
Affiliation:
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.
Kae Nakamura
Affiliation:
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.
Hiromasa Tanaka
Affiliation:
Department of Electrical Engineering and Computer Science, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan
Masaru Hori
Affiliation:
Department of Electrical Engineering and Computer Science, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan
Fumitaka Kikkawa
Affiliation:
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550, Japan.
Get access

Abstract

Epithelial ovarian carcinoma (EOC) is the leading cause of cancer-related death in women in Western countries. Once patients experience recurrence, complete cure is almost impossible. We elucidated the effect of nonequilibrium atmospheric pressure plasma on the growth of EOC, particularly in plasma-activated medium (PAM). Furthermore, we examined the role of reactive oxygen species (ROS) or their scavengers in chronic antineoplastic-resistant EOC cells. As a result, we showed PAM induced the antitumor effect of EOC cells in vitro and in vivo, even in chemoresistant cells. To apply the plasma treatment for advanced or recurrent EOC, we suggest adopting indirect plasma therapy instead of direct plasma considering intraperitoneal administration in the future. However, there are several problems under investigation, including intracellular mechanism of antitumor effect by PAM and adverse event in vivo.

Keywords

plasmadepositionArbiomedical
Type
Articles
Information
MRS Online Proceedings Library (OPL) , Volume 1598: Symposium O – Plasma Processing and Diagnostics for Life Sciences , 2013 , jsapmrs13-6006
Copyright
Copyright © Materials Research Society 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Teoh, D, et al. . Int J of Gynecol Cancer 22: 348–359 (2012).CrossRefGoogle Scholar
Usha, L, et al. . Gynecol Oncol 121: 455–461 (2011).CrossRefGoogle Scholar
Brun, P, et al. . Plos One 7 (2012).CrossRefGoogle Scholar
Fridman, G, et al. . Plasma Chemistry and Plasma Processing 26: 425–442 (2006).CrossRefGoogle Scholar
Lee, JK, et al. . Jpn J Appl Phys 50 (2011).Google Scholar
Kajiyama, H, et al. . Int J Oncol 31: 277–283 (2007).Google Scholar
Maeda, O, et al. . Int J Cancer 130: 113–121 (2012).CrossRefGoogle Scholar
Iseki, S, et al. . Applied Physics Letters 100 (2012).CrossRefGoogle Scholar